Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

F-031

Supelco

Fluconazole solution

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C13H12F2N6O
Número CAS:
86386-73-4
Peso molecular:
306.27
Número CE:
200-659-6
Número MDL:
MFCD00274549
Código UNSPSC:
41116107
ID de substância PubChem:
329799654
NACRES:
NA.24

grau

certified reference material

Formulário

liquid

Características

(Snap-N-Spike®)

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

concentração

2.0 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

clinical testing

Formato

single component solution

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

Fc1c(ccc(c1)F)C(O)(C[n]3ncnc3)C[n]2ncnc2

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

chave InChI

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órgãos-alvo

Eyes,Central nervous system

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

Hydroxyitraconazole 100 μg/mL in methanol, certified reference material, Cerilliant®

Supelco

H-110

Hydroxyitraconazole

Furosemide solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

F-005

Furosemide solution

Sigma-Aldrich

Sigma-Aldrich

R7388

Meio RPMI-1640

Voriconazole Pharmaceutical Secondary Standard: Certified Reference Material

Supelco

PHR1892

Voriconazole

Anfotericina B 250 μg/mL in deionized water, 0.1 μm filtered, BioReagent, suitable for cell culture

Sigma-Aldrich

A2942

Anfotericina B

Caspofungin diacetate ≥97% (HPLC)

Sigma-Aldrich

SML0425

Caspofungin diacetate

Maria I Rosa et al.
European journal of obstetrics, gynecology, and reproductive biology, 167(2), 132-136 (2013-01-03)
To investigate the efficacy, compared to placebo, of fluconazole 150 mg weekly, given for six months as prophylaxis against recurrent vulvovaginal candidiasis (RVVC). A quantitative systematic review was performed, and randomized controlled trials were included. We conducted searches at Medline
Theodoros Kelesidis et al.
Scandinavian journal of infectious diseases, 42(1), 12-21 (2010-01-09)
The increasing numbers of joint arthroplasties being undertaken, and the increase in patients with systemic illnesses undergoing the procedure, have contributed to a continuing increase in prosthetic joint infections. Candida prosthetic joint infection is a rare clinical entity, and only
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
K Turner et al.
Current medicinal chemistry, 19(27), 4617-4620 (2012-08-11)
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica